|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/10/17 Biolase, Inc 10-K 12/31/16 80:13M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.17M
2: EX-10.18 Material Contract HTML 26K
3: EX-10.19 Material Contract HTML 66K
4: EX-10.20 Material Contract HTML 56K
5: EX-10.21 Material Contract HTML 111K
6: EX-21.1 Subsidiaries List HTML 21K
7: EX-23.1 Consent of Experts or Counsel HTML 24K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
16: R1 Document and Entity Information HTML 52K
17: R2 Consolidated Balance Sheets HTML 114K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
19: R4 Consolidated Statements Of Operations And HTML 97K
Comprehensive Loss
20: R5 Consolidated Statements Of Shareholders' Equity HTML 100K
21: R6 Consolidated Statements Of Shareholders' Equity HTML 24K
(Parenthetical)
22: R7 Consolidated Statements Of Cash Flows HTML 137K
23: R8 Basis of Presentation HTML 43K
24: R9 Summary of Significant Accounting Policies HTML 168K
25: R10 Supplementary Balance Sheet Information HTML 186K
26: R11 Intangible Assets and Goodwill HTML 121K
27: R12 Income Taxes HTML 218K
28: R13 Commitments and Contingencies HTML 62K
29: R14 Stockholders' Equity HTML 454K
30: R15 Segment Information HTML 73K
31: R16 Concentrations HTML 66K
32: R17 Subsequent Events (Unaudited) HTML 30K
33: R18 Schedule II-Consolidated Valuation and Qualifying HTML 116K
Accounts and Reserves
34: R19 Summary of Significant Accounting Policies HTML 262K
(Policies)
35: R20 Summary of Significant Accounting Policies HTML 126K
(Tables)
36: R21 Supplementary Balance Sheet Information (Tables) HTML 191K
37: R22 Intangible Assets and Goodwill (Tables) HTML 115K
38: R23 Income Taxes (Tables) HTML 216K
39: R24 Commitments and Contingencies (Tables) HTML 36K
40: R25 Stockholders' Equity (Tables) HTML 416K
41: R26 Segment Information (Tables) HTML 69K
42: R27 Concentrations (Tables) HTML 64K
43: R28 Basis of Presentation - Additional Information HTML 87K
(Detail)
44: R29 Summary of Significant Accounting Policies - HTML 65K
Additional Information (Detail)
45: R30 Estimated Useful Lives of Property, Plant and HTML 36K
Equipment (Detail)
46: R31 Changes in Initial Product Warranty Accrual and HTML 37K
Expenses Under Initial and Extended Warranties
(Detail)
47: R32 Classification of Compensation Expense Associated HTML 36K
with Share-Based Payments (Detail)
48: R33 Assumptions Used in Estimating Fair Value of Stock HTML 32K
Options Granted (Detail)
49: R34 Components of Accounts Receivable, Net of HTML 31K
Allowance (Detail)
50: R35 Supplementary Balance Sheet Information - HTML 60K
Additional Information (Detail)
51: R36 Components of Inventory (Detail) HTML 32K
52: R37 Summary of Property, Plant, and Equipment (Detail) HTML 49K
53: R38 Components of Accrued Liabilities (Detail) HTML 46K
54: R39 Summary of Deferred Revenue (Detail) HTML 44K
55: R40 Intangible Assets and Goodwill - Additional HTML 28K
Information (Detail)
56: R41 Intangible Assets and Related Accumulated HTML 52K
Amortization (Detail)
57: R42 Summary of Income Tax Current and Deferred HTML 43K
Provision (Detail)
58: R43 Federal Income Tax Provision Compared With HTML 51K
Statutory Rates (Detail)
59: R44 Summary of Net Deferred Tax Assets and Net HTML 72K
Deferred Tax Liabilities (Detail)
60: R45 Income Taxes - Additional Information (Detail) HTML 54K
61: R46 Summary of Unrecognized Tax Benefits (Detail) HTML 29K
62: R47 Commitments and Contingencies - Additional HTML 91K
Information (Detail)
63: R48 Future Minimum Rental Commitments Under Lease HTML 36K
Agreements (Detail)
64: R49 Stockholders' Equity - Additional Information HTML 587K
(Detail)
65: R50 Summary of Stock Dividends Declared (Detail) HTML 36K
66: R51 Summary of Warrant Activity (Detail) HTML 52K
67: R52 Summary of Option Activity Under Stock Option HTML 78K
Plans (Detail)
68: R53 Options Outstanding and Exercisable (Detail) HTML 69K
69: R54 Cash Proceeds Along with Fair Value Disclosures HTML 34K
Related to Grants, Exercises, and Vesting Options
(Detail)
70: R55 Summary of Unvested Restricted Stock Units HTML 43K
(Detail)
71: R56 Segment Information - Additional Information HTML 38K
(Detail)
72: R57 Summary of Net Revenue by Geographic Location HTML 29K
(Detail)
73: R58 Summary of Long-Lived Assets by Geographic HTML 31K
Location (Detail)
74: R59 Concentrations - Summary of Net Revenue from HTML 39K
Various Products (Detail)
75: R60 Concentrations - Additional Information (Detail) HTML 31K
76: R61 Subsequent Events (unaudited) - Additional HTML 100K
Information (Detail)
77: R62 Consolidated Valuation and Qualifying Accounts and HTML 37K
Reserves (Detail)
79: XML IDEA XML File -- Filing Summary XML 137K
78: EXCEL IDEA Workbook of Financial Reports XLSX 104K
10: EX-101.INS XBRL Instance -- biol-20161231 XML 3.71M
12: EX-101.CAL XBRL Calculations -- biol-20161231_cal XML 211K
13: EX-101.DEF XBRL Definitions -- biol-20161231_def XML 683K
14: EX-101.LAB XBRL Labels -- biol-20161231_lab XML 1.54M
15: EX-101.PRE XBRL Presentations -- biol-20161231_pre XML 1.16M
11: EX-101.SCH XBRL Schema -- biol-20161231 XSD 216K
80: ZIP XBRL Zipped Folder -- 0001564590-17-003972-xbrl Zip 225K
Exhibit 10.18
Biolase, Inc.
4 Cromwell
BIOLASE, Inc.
4 Cromwell
Dear Harold,
The purpose of this letter is to acknowledge that, in consideration of the sum of $1.00 and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, you and BIOLASE, Inc. (the “Company”) have agreed that the restricted stock unit award granted to you on November 8, 2016, representing the right to acquire 1,000,000 shares of Company common stock pursuant to the terms of the BIOLASE, Inc. 2002 Stock Incentive Plan, as amended (the “Plan”), has been rescinded in its entirety. As discussed, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) intends to review your compensation in January 2017 and may, at such time, grant you equity awards upon such terms and conditions as approved by the Compensation Committee and which are consistent with the terms of the Plan.
Please acknowledge the foregoing by signing below and returning this letter to me at your earliest convenience. If you have any questions or otherwise wish to discuss, please do not hesitate to contact me.
Sincerely,
Jonathan T. Lord
Chairman of the Compensation Committee of the Board of Directors of BIOLASE, Inc.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/10/17 | |||
| For Period end: | 12/31/16 | SD | ||
| 11/23/16 | 4/A, 8-K | |||
| 11/22/16 | 8-K | |||
| 11/8/16 | 10-Q, 4, 4/A, 8-K | |||
| List all Filings | ||||